Sarep­ta touts Duchenne gene ther­a­py up­take, but warns of de­mand flat­ten­ing be­fore po­ten­tial ex­pand­ed la­bel from FDA

Sarep­ta Ther­a­peu­tics an­nounced Wednes­day af­ter­noon that its Duchenne mus­cu­lar dy­s­tro­phy gene ther­a­py Ele­v­idys pulled in $200 mil­lion in its first half-year on the com­mer­cial mar­ket.

In the fourth quar­ter of 2023, the gene ther­a­py’s sales jumped to $131.2 mil­lion, up from $69 mil­lion in the first few months it was on the mar­ket. All in all, the biotech eclipsed $1 bil­lion in sales in 2023 on all its Duchenne med­i­cines, which in­clude three “ex­on-skip­ping” drugs in ad­di­tion to the gene ther­a­py.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER